These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 26568161)
1. sec-Butylpropylacetamide (SPD) has antimigraine properties. Kaufmann D; Bates EA; Yagen B; Bialer M; Saunders GH; Wilcox K; White HS; Brennan KC Cephalalgia; 2016 Sep; 36(10):924-35. PubMed ID: 26568161 [TBL] [Abstract][Full Text] [Related]
2. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Kaufmann D; West PJ; Smith MD; Yagen B; Bialer M; Devor M; White HS; Brennan KC Pharmacol Res; 2017 Mar; 117():129-139. PubMed ID: 27890817 [TBL] [Abstract][Full Text] [Related]
3. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Shekh-Ahmad T; Mawasi H; McDonough JH; Yagen B; Bialer M Epilepsy Behav; 2015 Aug; 49():298-302. PubMed ID: 25979572 [TBL] [Abstract][Full Text] [Related]
4. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Pouliot W; Bialer M; Hen N; Shekh-Ahmad T; Kaufmann D; Yagen B; Ricks K; Roach B; Nelson C; Dudek FE Neuroscience; 2013 Feb; 231():145-56. PubMed ID: 23159312 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid. Mawasi H; Shekh-Ahmad T; Finnell RH; Wlodarczyk BJ; Bialer M Epilepsy Behav; 2015 May; 46():72-8. PubMed ID: 25863940 [TBL] [Abstract][Full Text] [Related]
6. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. White HS; Alex AB; Pollock A; Hen N; Shekh-Ahmad T; Wilcox KS; McDonough JH; Stables JP; Kaufmann D; Yagen B; Bialer M Epilepsia; 2012 Jan; 53(1):134-46. PubMed ID: 22150444 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. Mawasi H; Bibi D; Shekh-Ahmad T; Shaul C; Blotnik S; Bialer M Mol Pharm; 2016 Jul; 13(7):2492-6. PubMed ID: 27218460 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. Haines KM; Matson LM; Dunn EN; Ardinger CE; Lee-Stubbs R; Bibi D; McDonough JH; Bialer M Epilepsia; 2019 Feb; 60(2):315-321. PubMed ID: 30615805 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. Bibi D; Bialer M Epilepsia; 2020 Jan; 61(1):149-156. PubMed ID: 31957880 [TBL] [Abstract][Full Text] [Related]
10. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Bar-Klein G; Swissa E; Kamintsky L; Shekh-Ahmad T; Saar-Ashkenazy R; Hubary Y; Shrot S; Stetlander L; Eisenkraft A; Friedman A; Bialer M Epilepsia; 2014 Dec; 55(12):1953-8. PubMed ID: 25377630 [TBL] [Abstract][Full Text] [Related]
11. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. Hen N; Shekh-Ahmad T; Yagen B; McDonough JH; Finnell RH; Wlodarczyk B; Bialer M J Med Chem; 2013 Aug; 56(16):6467-77. PubMed ID: 23879329 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and mechanism of anticonvulsant drugs in migraine. Hoffmann J; Akerman S; Goadsby PJ Expert Rev Clin Pharmacol; 2014 Mar; 7(2):191-201. PubMed ID: 24494792 [TBL] [Abstract][Full Text] [Related]
14. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Shekh-Ahmad T; Hen N; McDonough JH; Yagen B; Bialer M Epilepsia; 2013 Sep; 54 Suppl 6(Suppl 6):99-102. PubMed ID: 24001086 [TBL] [Abstract][Full Text] [Related]
15. A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia. Bertels Z; Witkowski WD; Asif S; Siegersma K; van Rijn RM; Pradhan AA Headache; 2021 Jan; 61(1):170-178. PubMed ID: 33326598 [TBL] [Abstract][Full Text] [Related]
16. δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. Pradhan AA; Smith ML; Zyuzin J; Charles A Br J Pharmacol; 2014 May; 171(9):2375-84. PubMed ID: 24467301 [TBL] [Abstract][Full Text] [Related]
17. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Tozzi A; de Iure A; Di Filippo M; Costa C; Caproni S; Pisani A; Bonsi P; Picconi B; Cupini LM; Materazzi S; Geppetti P; Sarchielli P; Calabresi P Proc Natl Acad Sci U S A; 2012 Nov; 109(46):18985-90. PubMed ID: 23112192 [TBL] [Abstract][Full Text] [Related]